<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-12002856</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2012-12-25</date_registration>
      <primary_sponsor>Bone marrow transplant center, 1st Affiliated Hospital, Zhejiang University</primary_sponsor>
      <public_title>Short-Time Second Generation Tyrosine Kinase inhibitors Combined With Allogeneic Stem Cell Transplantation for Patients with Imatinib-refractory CML</public_title>
      <acronym />
      <scientific_title>Short-Time Second Generation Tyrosine Kinase inhibitors Combined with by Allogeneic Stem Cell Transplantation for Patients with Imatinib-refractory CML</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2012-12-01</date_enrolment>
      <type_enrolment />
      <target_size>2nd TKI combined with SCT:20;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6698</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>Other</phase>
      <hc_freetext>chronic myeloid leukemia</hc_freetext>
      <i_freetext>2nd TKI combined with SCT:short-time second-generation tyrosine kinase inhibitors (TKI) used before and after allo-SCT  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Yanmin Zhao</firstname>
        <middlename />
        <lastname />
        <address>Bone marrow transplant center, 1st Affiliated Hospital, Zhejiang University, Hangzhou 310003, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15858199217</telephone>
        <email>zjzhaoyanmin@163.com</email>
        <affiliation>Bone marrow transplant center, 1st Affiliated Hospital, Zhejiang University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>He Huang</firstname>
        <middlename />
        <lastname />
        <address>Bone marrow transplant center, 1st Affiliated Hospital, Zhejiang University, Hangzhou 310003, China</address>
        <city />
        <country1 />
        <zip>310003</zip>
        <telephone>+86 13605714822</telephone>
        <email>hehuangyu@126.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. gave informed consent;
2. age less than 60 years;
3. diagnosed with CML, as confirmed by the presence of the Philadelphia (Ph) chromosome or the BCR-ABL fusion gene;
4. imatinib treatment failure.</inclusion_criteria>
      <agemin>12</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. severe irreversible comorbidity, such as renal, hepatic, pulmonary, or cardiac disease;
2. development of grade &gt;=3 adverse events during 2nd TKIs therapy; 
3. pregnancy or lactation;
4. has T315I BCR-ABL kinase domain mutation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>3- year Overall Survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>3-year disease free survival;engraftment rate;3- year cumulative relapse rate;Response rate to 2nd TKI;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Natural Science Foundation of China</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-12-29</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>